If you work in wound care billing or manage a practice that uses cellular tissue-based products (CTPs), January 1, 2026 brought some of the most significant Medicare reimbursement changes in recent memory. These updates have reshaped how skin substitutes are coded, billed, and paid — and the financial impact on providers and outpatient hospitals is substantial.
Here’s a clear, practical breakdown of what changed, why it changed, and what your practice needs to do right now.
Why Did Medicare Change CTP Reimbursement Rules?
The short answer: explosive cost growth that raised major red flags.
Between 2019 and 2024, Medicare Part B payments for skin substitutes skyrocketed from $252 million to over $10 billion — a staggering increase driven in large part by fraud, waste, and abuse. Under the old system, skin substitutes were treated as Part B drugs and biologicals, reimbursed at the Average Sales Price (ASP) plus 6% — a methodology that proved easy to exploit.
CMS responded with sweeping rule changes designed to save an estimated $9.4 billion, fundamentally restructuring how these products are classified and reimbursed.
The New Flat Rate and “Incident-To” Classification
Under the 2026 rules, Medicare set a flat rate of $127.14 per square centimeter for CTPs that do not meet the licensing requirements for biologicals under Section 351 of the Public Health Service (PHS) Act.
CTPs that are unlicensed as biologicals are now classified as “incident-to” supplies, meaning they are bundled into the practice expense of the graft application procedure rather than billed separately as a product. These policies apply across hospital outpatient facilities, patient homes, and qualified healthcare professional offices.
Understanding the Four Clinical Classifications of CTPs
Before diving into coding changes, it helps to understand how CTPs are clinically defined. There are four categories:
Human skin allografts — derived from donated human skin
Allogeneic matrices — derived from human tissues such as fibroblasts
Composite matrices — derived from human keratinocytes, fibroblasts, and xenogenic collagen
Acellular matrices — derived from xenogenic collagen or tissue
Each type follows different FDA regulatory pathways, which directly determines how it gets reimbursed under the new system.
FDA Regulatory Pathways and How They Drive Payment
Understanding FDA approval types is now essential for accurate CTP billing. There are three primary pathways:
Section 361 HCT/Ps — These products do not require clinical trials before going to market. They are FDA-registered (not FDA-approved) and must comply with current good tissue practice (CGTP) requirements focused on preventing the spread of communicable diseases.
Section 351 Biological Products — Used to prevent, cure, or treat specific conditions, these require pre-market FDA 510(k) clearance. They are considered true biologicals and continue to be reimbursed at the traditional ASP plus 6% rate.
Premarket Approval (PMA) — Reserved for high-risk medical devices, PMA designation requires extensive evidence of clinical safety and efficacy before a product can reach the market.
Key Coding Changes Effective January 1, 2026
New CPT Codes Replace Deleted HCPCS Codes
One of the biggest structural shifts is the unbundling of CTPs from procedure payments in hospital outpatient departments. The procedure and the product are now reimbursed separately.
HCPCS codes C5271–C5278, previously used for low-cost skin substitute procedures under the Outpatient Prospective Payment System (OPPS), were deleted effective January 1, 2026.
In their place, CPT codes 15271–15278 were added as skin substitute application procedure codes, applicable to all CTP applications. These codes should not be used for non-graft wound dressings or biologic implants for soft tissue reinforcement.
New Status Indicator: S1
The January 2026 Outpatient Code Editor (OCE) update introduced status indicator S1, which applies to sheet form skin substitute products that are paid separately. Importantly, if a skin substitute application procedure is submitted without a corresponding S1-designated product code, the OCE editor will return an edit — meaning your claim won’t process cleanly.
Non-sheet form skin substitutes carry a status indicator of N, meaning they are packaged into Ambulatory Payment Classification (APC) rates.
Three New APCs Based on FDA Pathway
Medicare introduced three new APCs for skin substitutes, organized by FDA regulatory pathway rather than by brand name or ASP:
APC 6000 — PMA skin substitute products (unlisted code: Q4431)
APC 6001 — FDA 510(k) cleared products (unlisted code: Q4432)
APC 6002 — 361 HCT/Ps (unlisted code: Q4433)
The WISeR Model: Prior Authorization Is Now a Reality
Adding another layer of complexity, CMS introduced the Wasteful and Inappropriate Service Reduction (WISeR) Model on January 5, 2026, covering dates of service from January 15, 2026 through January 31, 2031.
CPT codes 15271–15278 for Original Medicare beneficiaries are now subject to prior authorization or pre-payment medical review under this model. Initially rolled out in four states — New Jersey, Ohio, Oklahoma, and Texas — the model applies to claims submitted for services in:
- Place of Service 11 (office)
- Place of Service 12 (home)
- Place of Service 24 (ASC)
Claims submitted without prior authorization in these settings will trigger pre-payment medical review. Providers in all states should monitor this closely, as all Medicare Administrative Contractors (MACs) have been tasked with oversight.
Local Coverage Determinations (LCDs) You Need to Know
Two active LCDs are currently driving coverage decisions for lower extremity wound care:
LCD L35041 — Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds
LCD L36690 — Wound Application of CTPs, Lower Extremities
Both require prior approval for traditional Medicare beneficiaries. Coverage hinges on the wound meeting the definition of a chronic non-healing wound — specifically, one that fails to show evidence of healing by contraction and epithelial margin advancement after four weeks of optimized standard therapy.
Coverage also requires that the patient be under the care of a physician licensed to treat the systemic disease process underlying the wound, such as venous insufficiency, diabetes, or neuropathy.
Documentation Requirements for Prior Authorization
Getting prior authorization approved means having thorough, well-organized documentation. Both the WISeR Model and the LCDs focus heavily on the following:
Wound Size
The wound or ulcer must be documented at baseline — including size, location, stage, duration, and infection status — along with its progression through treatment. The deficit must measure at least 1.0 square centimeter.
Wound Depth
Coverage applies to partial- or full-thickness ulcers, provided the wound does not involve tendon, muscle, joint capsule, exposed bone, or sinus tracts — unless the CTP’s label specifically states it is approved for those conditions.
Wound Quality
The wound bed must have a clean granular base and be free of necrotic debris or exudate. Documentation should clearly note this.
Ankle-Brachial Index (ABI)
Adequate circulation to support wound healing must be documented — typically an ABI of no less than 0.60 or a toe pressure greater than 30 mmHg.
Failed Response Documentation
Records must clearly explain why prior wound care measures failed — whether the wound increased in size or depth, or showed no improvement from baseline.
No More Reimbursement for Discarded Product
This is a critical change many providers may overlook. Medicare no longer reimburses for discarded skin substitute products, regardless of whether a JW or JZ modifier is used.
The rule is simple: you can only bill for what you actually apply to the patient.
If you open a 6×6 cm sheet of a 361 HCT/P product and use only 5×5 cm of it, you bill for 25 sq. cm — not 36 sq. cm. Billing for the full sheet would constitute overbilling.
Compliance Recommendations for Your Practice
The Office of the Inspector General (OIG) will continue actively monitoring skin substitute billing given the extensive fraud uncovered in recent years. If your practice previously received thousands of dollars in reimbursement for these products, it’s time to recalibrate your financial projections.
Here’s what to do now:
- Update your charge description master (CDM) to reflect the new CPT and HCPCS codes
- Implement pre-authorization workflows for all applicable skin substitute procedures
- Train billing and coding staff on the new APC structure and S1 status indicator rules
- Conduct post-payment reviews after payment posting to catch discrepancies early
- Monitor LCD and WISeR updates in your state, as coverage policies are still evolving
The Bottom Line
The 2026 Medicare CTP rule changes are not just a coding update — they represent a fundamental shift in how skin substitute products are regulated, classified, and reimbursed. Providers who fail to adapt risk claim denials, compliance exposure, and significant revenue loss.
Stay current, document thoroughly, and build strong prior authorization processes now. The regulatory environment around CTPs is still evolving, and the practices that thrive will be the ones that treat compliance as an ongoing priority — not an afterthought.
